Pimobendan (CAS 74150-27-9) is a high-quality active pharmaceutical ingredient (API) produced according to strict in-house standards. It is widely used in veterinary medicine, specifically for managing mild to severe congestive heart failure (CHF) in dogs caused by atrioventricular insufficiency or myocardial hypertrophy. As a benzimimidazole-pyridazinone derivative, Pimobendan plays a vital role in improving cardiac function and overall quality of life in canine patients.

Applications

Pimobendan has been FDA-approved for treating canine heart failure since 2007. In the United States, it is primarily prescribed for dogs with:

• Dilated Cardiomyopathy (DCM)
• Degenerative Mitral Valve Disease (DMVD)

Pimobendan is an inodilator that causes arterial and venous dilatation while concurrently boosting the heart's contractility (positive inotropic action). It is a key treatment for CHF in veterinary practice because of these combined effects, which lessen the strain on the heart and improve blood flow.

Tolerability and Safety

In dogs, pimobendan is usually safe and well accepted. When taken as chewable tablets, side effects are rare and usually restricted to minor gastrointestinal issues. But a large dosage could result in toxicity, which could manifest as:

• Extreme tachycardia
• Slight variations in blood pressure

To guarantee safe and efficient treatment, proper dosage and veterinary supervision are crucial.